Equities Analysts Issue Forecasts for TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Taysha Gene Therapies in a research note issued on Wednesday, November 5th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.37) per share for the year, down from their previous estimate of ($0.34). The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share. Cantor Fitzgerald also issued estimates for Taysha Gene Therapies’ FY2026 earnings at ($0.48) EPS.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.51 million.

A number of other analysts have also recently commented on the company. Wells Fargo & Company upped their price target on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Taysha Gene Therapies in a research note on Thursday, October 30th. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Taysha Gene Therapies in a research note on Friday, October 17th. Robert W. Baird lifted their price target on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a report on Thursday, October 2nd. Finally, Raymond James Financial initiated coverage on shares of Taysha Gene Therapies in a research report on Tuesday, October 21st. They issued a “strong-buy” rating and a $13.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Moderate Buy” and an average target price of $9.70.

Taysha Gene Therapies Price Performance

Shares of Taysha Gene Therapies stock opened at $3.92 on Friday. The stock has a market cap of $1.07 billion, a P/E ratio of -11.88 and a beta of 1.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.48 and a current ratio of 10.48. The stock’s fifty day moving average is $3.97 and its 200 day moving average is $3.05. Taysha Gene Therapies has a one year low of $1.05 and a one year high of $5.51.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds have recently made changes to their positions in the company. Allegheny Financial Group bought a new position in Taysha Gene Therapies during the third quarter valued at approximately $49,000. Rhumbline Advisers increased its stake in Taysha Gene Therapies by 23.8% in the 3rd quarter. Rhumbline Advisers now owns 288,859 shares of the company’s stock worth $945,000 after acquiring an additional 55,603 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Taysha Gene Therapies by 100.6% during the 3rd quarter. Profund Advisors LLC now owns 53,366 shares of the company’s stock worth $175,000 after acquiring an additional 26,767 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Taysha Gene Therapies by 33.6% during the 3rd quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock valued at $53,000 after acquiring an additional 4,091 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in shares of Taysha Gene Therapies by 220.4% in the third quarter. New York State Common Retirement Fund now owns 67,600 shares of the company’s stock valued at $221,000 after purchasing an additional 46,500 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the transaction, the insider directly owned 1,006,439 shares of the company’s stock, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.78% of the stock is currently owned by company insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.